ERBB2 and breast carcinoma: Our in vitro and in vivo studies demonstrate that the EGFR and HER2 FolTAC-dual degrader effectively suppresses tumor growth in Trastuzumab/Lapatinib-resistant HER2-positive breast cancer (HER2 + BC) models34,35.